Pricing & Access· May 27, 2026 · 10 min readTezspire coverage guide: tezepelumab severe asthma and CRSwNP access, biomarker-light positioning, benefit routing, and Fast Start supportTezspire (tezepelumab-ekko) is a TSLP blocker approved for severe asthma and chronic rhinosinusitis with nasal polyps. This guide...By Ran Chen#Respiratory#Prior Authorization#Payer Policy
Biosimilars· May 27, 2026 · 11 min readXolair and Omlyclo access guide: omalizumab reference product and first interchangeable biosimilar, indication routing across asthma, CRSwNP, food allergy, and CSU, medical vs pharmacy benefit, interchangeability substitution, and payer switchingXolair (omalizumab, Genentech/Novartis) is an anti-IgE monoclonal antibody approved for allergic asthma, chronic rhinosinusitis with...By Ran Chen#Biosimilars#Interchangeability#Prior Authorization
